ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacoepidemiology
This article is part of the Research TopicInnovative Approaches in Pharmacovigilance: Enhancing Detection and Analysis of Adverse Drug Reactions in Clinical and Real-World SettingsView all 12 articles
Hydrochlorothiazide and Chlorthalidone Use and Glaucoma Risk: Pharmacovigilance Analysis and Nationwide Cohort Study
Provisionally accepted
- 1Hanyang University, Seoul, Republic of Korea
- 2Asan Medical Center, Songpa-gu, Republic of Korea
- 3Hanyang University - ERICA Campus, Ansan-si, Republic of Korea
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Hydrochlorothiazide and chlorthalidone are widely used thiazide diuretics, and pharmacovigilance reports have suggested a possible link between their use and glaucoma. Therefore, this study aims to evaluate whether the use of hydrochlorothiazide or chlorthalidone is associated with an increased risk of glaucoma in a nationwide population-based claims cohort to clarify the true risk and guide clinical practice. Pharmacovigilance disproportionality analyses of the Food and Drug Administration Adverse Event Reporting System (FAERS) reports were conducted to identify candidates for glaucoma-related diuretics. In the nationwide Korean Health Insurance Review and Assessment (HIRA) cohort of new users of hydrochlorothiazide or chlorthalidone, incidence of overall and subtype-specific glaucoma was assessed, and pre-and post-exposure incidence rate ratios (IRRs) were calculated. Multivariate Cox proportional hazards models were used to estimate hazard ratios (HRs) for clinical risk factors. Hydrochlorothiazide and chlorthalidone demonstrated positive disproportionality signals for glaucoma (ROR, 3.34; 95% confidence interval [CI], 2.85–3.91 and 11.37; 95% CI, 7.67–16.86, respectively). In the HIRA cohort of new users of hydrochlorothiazide (n=250,296) or chlorthalidone (n=10,005) from January 2019 to December 2020, the cumulative incidence of glaucoma/ocular hypertension rose gradually for both drugs, reaching approximately 2– 3% by study end. Pre-versus post-exposure IRRs for overall glaucomatous conditions were 1.02 (95% CI 0.98–1.06) for hydrochlorothiazide and 1.03 (95% CI 0.84–1.26) for chlorthalidone; IRRs for ocular hypertension were 1.02 (95% CI 0.97–1.07) and 1.09 (95% CI 0.87–1.37), respectively. Multivariate analyses found no significant association between the drugs and overall glaucomatous conditions (adjusted HR 1.01; 95% CI 0.86–1.19). In dose-stratified analyses, hydrochlorothiazide showed a modest increase in glaucoma risk in the highest cumulative exposure group (for overall glaucomatous conditions, HR 1.21; 95% CI 1.12–1.31; log-rank P < 0.01), whereas chlorthalidone showed no consistent dose–response trends. Although the FAERS pharmacovigilance suggested a potential glaucoma risk with hydrochlorothiazide and chlorthalidone, population-based validation found no significant association. Pharmacovigilance signals should be confirmed with population-based data to identify true drug–glaucoma associations.
Keywords: adverse event reporting system, Chlorthalidone, Diuretics, Glaucoma, Hydrochlorothiazide, Pharmacovigilance, Thiazide
Received: 15 Dec 2025; Accepted: 10 Feb 2026.
Copyright: © 2026 Yoon, Kim, Kim, Chung and Ahn. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Seong Joon Ahn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.